Evaluation of treatment of leukoplakia with antioxidant tablets through blood test

COMPARISON OF SERUM AND SALIVARY MALONDIALDEHYDE LEVELS IN ORAL LEUKOPLAKIA SUBJECTS BEFORE AND AFTER TREATMENT WITH ANTIOXIDANTS AN INTERVENTIONAL STUDY

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/01/017358

Enrollment

Registered

2019-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z789- Other specified health status

Interventions

Intervention1: Rivaz-plus tablet consisting of lycopene vit A vit E Vit C Zinc sulphate: Marketed by Eviza Biotech Pharmaceuticals Tablets three times a day for 4 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male Subjects aged 18 years and above with (G2 & G3) & without (G1) habit of tobacco consumption (tobacco, chewing with betel quid or tobacco smoking and alcohol consumption) 2. Willing to give written informed consent .

Exclusion criteria

Exclusion criteria: Alcoholics 2. Known Systemic diseases (coronary heart disease, renal disease, parasitic infections etc) or any malignancy.

Design outcomes

Primary

Measure	Time frame
To Compare Serum & Salivary Malondialdehyde Levels in Oral Leukoplakia subjects before and after treatment with antioxidants.Timepoint: 4 weeks after antioxidant therapy	—

Secondary

Measure	Time frame
To access the reduction in serum and salivary malondialdehyde levels after four weeksTimepoint: Four weeks	—

Countries

India

Contacts

Public ContactFarheen

Swami Devi Dyal Hospital and Dental college

rajesh42gupta@gmail.com9815711852

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026